The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
Age ≥50 years
Lp(a)≥ 200 nmol/L during screening
Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
Prior or planned arterial revascularization
History of major bleeding disorder